Safety and Efficacy of Oncoxin in Hepatocellular Carcinoma (HCC)

Clinical Research Organization, Dhaka, Bangladesh

Status and phase

Unknown

Phase 2

Phase 1

Conditions

Hepatocellular Carcinoma

Treatments

Other: Supportive treatment

Dietary Supplement: Oncoxin

Study type

Interventional

Funder types

Other

Identifiers

OP1

Details and patient eligibility

About

Oncoxin is safe and results in improved survival in patients with hepatocellular carcinoma

Full description

To assess therapeutic efficacy and safety of Oncoxin in hepatocellular carcinoma

To see if there is reduction in serum alpha fetoprotein level in hepatocellular carcinoma patients after administration of Oncoxin

To see if there is reduction tumor size and or number in hepatocellular carcinoma patients after administration of Oncoxin

To see if there is improvement of quality of life in hepatocellular carcinoma patients after administration of Oncoxin

To see if there is improved survival in hepatocellular carcinoma patients after administration of oncoxin

Enrollment

40 estimated patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients with HCC irrespective of etiology, age, gender and status of underlying liver disease.
Patients with HCC who are not suitable candidates for established modalities of treatment i.e. surgery and/or chemotherapy.
Patients with HCC who have evidence of tumor metastasis
Patients with HCC who are voluntarily unwilling to take established modalities of treatment i.e. surgery and/or chemotherapy.
Patients with HCC in whom all possible treatment options have been exhausted.

Exclusion criteria

Patients with HCC who are suitable candidates for established modalities of treatment i.e. surgery and/or chemotherapy.
Patients with HCC who have no evidence of tumor metastasis
Patients with HCC who are willing to take established modalities of treatment i.e. surgery and/or chemotherapy.
Patients with HCC who are voluntarily unwilling to be included in the trial